drugset / Trial / NCT03529825
Rifaximin for Infection Prophylaxis in Hematopoietic Stem Cell Transplantation
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Primary purpose of the study is to see if rifaximin can improve the balance of bacteria within the gut, which has been shown to improve transplant outcomes. It will also assess whether rifaximin can reduce the risk of infection in blood/marrow transplant (BMT).
Timeline
- Start
- 2018-07-18
- Primary completion
- 2020-10-19
- Completion
- 2021-09-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rifaximin | Other / unclassified | 15 mg/kg | Oral |
Indications
No indication recorded.